Beraprost
As of the edition of 20 October 2026, Beraprost is a small molecule: stopped in 2016; acts on PTGIR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2016
- Kind
- Small molecule
- Registered trials
- 17, 2 stopped early
- Disease areas
- Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Beraprost.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGIR | Prostacyclin receptor | P43119 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 4 | 3 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 3 | 2 | 0 | 1 |
| Phase 4 | 3 | 1 | 0 | 1 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Toray Industries | Lead sponsor of trials | 2005 to now |
| Astellas | Lead sponsor of trials | 2008 to now |
| Lung Biotechnology PBC | Lead sponsor of trials | 2009 to now |